Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.
Luke Greenwalt
Advertisement
VP, U.S. Thought Leadership & Innovation, IQVIA
Articles by Luke Greenwalt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
How Will TrumpRx Impact Manufacturer-Produced DTC Programs?
4
Shifting Focus in Autoimmune Diseases
5
